Navegando por Palavras-chave "Antidepressant"
Agora exibindo 1 - 7 de 7
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosCan antidepressants prevent interferon-alpha-induced depression? A review of the literature(Elsevier B.V., 2010-07-01) Galvao-de Almeida, Amanda [UNIFESP]; Guindalini, Camila [UNIFESP]; Batista-Neves, Susana; Oliveira, Irismar R. de; Miranda-Scippa, Angela; Quarantini, Lucas C.; Universidade Federal da Bahia (UFBA); Universidade Federal de São Paulo (UNIFESP); Lab Interdisciplinar Neurociencias Clin LiNCObjective: To review the literature about the efficacy of antidepressant prophylaxis during interferon-alpha (IFN-alpha) therapy.Method: We have performed a database search in PUBMED and ISI Web of Knowledge (1980-August 2009) for the available literature. the keywords prevention or prophylaxis, and depression, and interferon, and antidepressant or antidepressive agents were used.Results: the six eligible studies comprise three randomized controlled trials, two in hepatitis C virus (HCV) patients and one in individuals with melanoma, and three open-label studies with HCV patients. the results of the randomized controlled trials suggest that antidepressant prophylaxis may blunt the magnitude of depressive symptoms in HCV patients and raise the rates of treatment completion. in melanoma patients, this preventive strategy may reduce the incidence of depression during IFN-alpha treatment. in addition, the open-label studies with HCV patients suggest that this strategy may reduce the onset of major depression in specific samples (current psychiatric diagnosis, major depression in remission, past history of IFN-alpha-induced depression) on IFN-alpha (re-)treatment.Conclusions: in the face of so few trials about the usefulness of prophylaxis with antidepressants before IFN-alpha treatment, there is not enough information to sufficiently and widely support this strategy to prevent depression. However, this approach may, nonetheless, bring some beneficial outcomes, if applied to specific patient groups. (C) 2010 Elsevier Inc. All rights reserved.
- ItemSomente MetadadadosChronic mild stress induces widespread decreases in thyroid hormone alpha(1) receptor mRNA levels in brain-Reversal by imipramine(Elsevier B.V., 2009-02-01) Stein, Edward J.; Silveira Filho, Nylson Gomes da [UNIFESP]; Machado, Danilo C. [UNIFESP]; Hipolide, Debora C. [UNIFESP]; Barlow, Karen; Nobrega, Jose N.; Ctr Addict & Mental Hlth; Univ Toronto; Universidade Federal de São Paulo (UNIFESP)While considerable clinical evidence implicates thyroid hormones (THs) in depressive illness, the specific nature of this involvement remains unclear. the alpha(1) subtype (TR-alpha(1)) is the most abundant TH receptor in brain. Here we investigated changes in TR-alpha(1) mRNA in the chronic mild stress (CMS) model of depression. Rats were exposed to a CMS schedule for 3 weeks, which resulted in a progressive decreases in sucrose preference (an index of anhedonia). They were then treated daily with either imipramine (IMI, 10 mg/kg) or vehicle (VEH) for 2 weeks before being sacrificed for quantitative in situ hybridization analyses of TR-alpha(1) mRNA throughout the brain.Results indicated that CMS followed by VEH induced widespread decreases in TR-alpha(1) mRNA in brain. in contrast, CMS-exposed rats receiving IMI for the last 2 weeks prior to sacrifice showed full recovery of sucrose preference. Furthermore, brain TR-alpha(1) mRNA levels in these animals were similar to those of non-stressed controls receiving either SAL or IMI. These results reveal that TR-alpha(1) mRNA brain levels are very sensitive to CMS effects. the reversal of both anhedonic and TR-alpha(1) effects of CMS by IMI suggests that TR-alpha(1) may play a role both in stress-induced depressive symptoms and in their reversal by antidepressant interventions. (C) 2008 Elsevier B.V. All rights reserved.
- ItemSomente MetadadadosControl of stress-induced acth secretion by vasopressin and crh: additional evidence(Karger, 2016) Ramos, Adriana T. [UNIFESP]; Tufik, Sergio [UNIFESP]; Troncone, Lanfranco R. P.Vasopressin and CRH have complementary roles in the secretion of ACTH following different stress modalities. The concomitant use of V-1b and CRF1 receptor antagonists completely inhibits ACTH secretion in response to different stress modalities. The combination of the CRF1 antagonist SSR125543 with the V-1b antagonist SSR149415 effectively suppressed plasma ACTH 1.30 h after injection in rats stressed by ether vapor inhalation for 1 min, restraint stress for 1 h or forced swimming for 5 min. The duration of the effect was also studied. The CRF1 antagonist effectively suppressed ACTH secretion in restraint stress, while the V-1b antagonist was effective against ether inhalation. Both antagonists were necessary to block the forced swimming stress response. SSR125543 induced a prolonged effect and can be used in a model of prolonged HPA axis blockade. (C) 2016 S. Karger AG, Basel
- ItemSomente MetadadadosEfficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review(Elsevier Science Bv, 2018) Lee, Yena; Rosenblat, Joshua D.; Lee, JungGoo; Carmona, Nicole E.; Subramaniapillai, Mehala; Shekotikhina, Margarita; Mansur, Rodrigo B.; Brietzke, Elisa [UNIFESP}; Lee, Jae-Hon; Ho, Roger C.; Yim, Samantha J.; McIntyre, Roger S.Introduction: Work-related disability and productivity loss in Major Depressive Disorder (MDD) are critical determinants of patient quality of life and contribute significantly to the human and economic costs of MDD. Notwithstanding the return to work and pre-morbid levels of functioning as a critical therapeutic objective among individuals with MDD, it is unclear whether antidepressant treatment significantly and reliably improves measures of workplace functioning. Herein, we investigate to what extent antidepressant treatment improves workplace functioning among adults with MDD. Methods: We conducted a systematic review of randomized, double-blind, placebo-controlled or active comparator clinical trials primarily or secondarily investigating the efficacy of antidepressant agents on subjective ratings of workplace functioning and/or measures of work absence. Results: Thirteen placebo-controlled and four active comparator clinical trials reported on the efficacy of agomelatine, bupropion, desvenlafaxine, duloxetine, fluoxetine, levomilnacipran, paroxetine, sertraline, venlafaxine, or vortioxetine on subjective measures of workplace impairment. Overall, antidepressant treatment improved standardized measures of workplace functioning (e.g., Sheehan Disability Scale-work item). One placebo-controlled trial of agomelatine and one clinical trial comparing the efficacy of vortioxetine to that of venlafaxine had mixed results on measures of work absence. Limitations: Included interventional trials evaluated work-related disability as a secondary outcome using subjective rating scales. Conclusion: Extant data suggest that antidepressant treatment improves workplace outcomes in MDD. The capability of antidepressants in improving measures of workplace functioning should be considered in cost-benefit analyses to better inform cost-modelling studies pertaining to antidepressant therapy.
- ItemSomente MetadadadosHippocampal volume and the rapid antidepressant effect of ketamine(Sage Publications Ltd, 2015-05-01) Abdallah, Chadi G.; Salas, Ramiro; Jackowski, Andrea [UNIFESP]; Baldwin, Philip; Sato, Joao R. [UNIFESP]; Mathew, Sanjay J.; Natl Ctr Posttraumat Stress Disorder PtSD; Yale Univ; Baylor Coll Med; Universidade Federal de São Paulo (UNIFESP); Universidade Federal do ABC (UFABC); Michael E Debakey Vet Adm VA Med CtrAccumulating evidence underscores the utility of ketamine in treating severely treatment-resistant depressed patients. We investigated the relationship between the rapid antidepressant effects of ketamine and hippocampal volume, a biomarker of antidepressant treatment outcome. We gave 16 medication-free, major depressive disorder (MDD) patients a single, sub-anesthetic dose infusion of ketamine (0.5 mg/kg, over 40 min). We assessed depression severity pre-treatment, and at 24 h post-treatment, with the Montgomery-angstrom sberg Depression Rating Scale (MADRS). Prior to treatment, patients underwent magnetic resonance imaging (MRI) to estimate their hippocampal volume: We obtained viable MRI data in 13 patients. Delta MADRS (post- minus pre-treatment) was significantly correlated with the pre-treatment volumes of the left hippocampus (r = 0.66; p = 0.01), but not the right hippocampus (r = 0.49; p = 0.09). the correlation between delta MADRS and the left hippocampus remained high (r > 0.6; p = 0.13), after controlling for several demographic and clinical variables, although the p value increased due to the reduced degree of freedom (df = 5). Ketamine exerts enhanced antidepressant effects in patients with a relatively smaller hippocampus, a patient population that has been repeatedly shown to be refractory to traditional antidepressants.
- ItemAcesso aberto (Open Access)Proconvulsant effects of high doses of venlafaxine in pentylenetetrazole-convulsive rats(Associação Brasileira de Divulgação Científica, 2002-04-01) Santos-Junior, Jair Guilherme [UNIFESP]; Do Monte, F.h.m.; Russi, M.; Agustine, P.e.; Lanziotti, Vanusa Maria Nascimento Bispo; Universidade Federal de São Paulo (UNIFESP); Universidade do Estado de Santa Catarina Centro de Ciências Agroveterinárias Departamento de MorfofisiologiaVenlafaxine, an atypical antidepressant drug, has been used to treat several neurological disorders, presenting excellent efficacy and tolerability. Clinical seizures after venlafaxine treatment have occasionally been reported when the drug was used at very high doses or in combination with other medications. The aim of the present study was to investigate the convulsant effects of venlafaxine in rats under controlled laboratory conditions. Adult male Wistar rats (8 per group) receiving venlafaxine or saline at the doses of 25-150 mg/kg were subjected 30 min later to injections of pentylenetetrazole at the dose of 60 mg/kg. The animals receiving 75, 100 and 150 mg/kg venlafaxine presented increased severity of convulsion when compared to controls (P = 0.02, P = 0.04, and P = 0.0004, respectively). Indeed, an increased percentage of death was observed in these groups (50, 38, and 88%, respectively) when compared to the percentage of death in the controls (0%). The group receiving 150 mg/kg showed an reduction in death latency (999 ± 146 s) compared to controls (1800 ± 0 s; cut-off time). Indeed, in this group, all animals developed seizures prior to pentylenetetrazole administration. Surprisingly, the groups receiving venlafaxine at the doses of 25 and 50 mg/kg showed a tendency towards an increase in the latency to the first convulsion. These findings suggest that venlafaxine at doses of 25 and 50 mg/kg has some tendency to an anticonvulsant effect in the rat, whereas doses of 75, 100 and 150 mg/kg presented clear proconvulsant effects in rats submitted to the pentylenetetrazole injection. These findings are the first report in the literature concerning the role of venlafaxine in seizure genesis in the rat under controlled conditions.
- ItemAcesso aberto (Open Access)Subchronical treatment with Fluoxetine modifies the activity of the MCHergic and hypocretinergic systems. Evidences from peptide CSF concentration and gene expression(Elsevier Science Bv, 2016) Calegare, Bruno F. [UNIFESP]; Costa, Alicia; Fernandes, Leandro [UNIFESP]; Dias, Ana L. [UNIFESP]; Torterolo, Pablo; D'Almeida, Vania [UNIFESP]In the postero-lateral hypothalamus are located two neuronal systems that utilize the neuropeptides melanin-concentrating hormone (MCH) and hypocretins (also called orexins) as neuromodulators. These systems have reciprocal connections between them, and project throughout the central nervous system. MCH has been involved in the generation of sleep, mainly REM sleep, while hypocretins have a critical role in the generation of wakefulness. MCHergic activity is also involved in the pathophysiology of major depressive disorder (MD). In this regards, intracerebral administration of MCH promotes pro-depressive behaviors (i.e., immobility in the forced swimming test) and REM sleep hypersomnia, which is an important trait of depression. Furthermore, the antagonism of the MCHR-1 receptor has a reliable antidepressant effect, suggesting that MCH is a pro-depressive factor. Hypocretins have been also involved in mood regulation; however, their role in depression is still on debate. Taking these data into account, we explored whether systemic subchronical treatment with Fluoxetine (FLX), a serotonergic antidepressant, modifies the concentration of MCH in the cerebrospinal fluid (CSF), as well as the preproMCH mRNA expression. We also evaluated the hypocretinergic system by quantifying the hypocretin-levels in the CSF and the preprohypocretin mRNA expression. Compared to control, FLX increased the levels of preprohypocretin mRNA without affecting the hypocretin-1 CSF levels. On the contrary, FLX significantly decreased the MCH CSF concentration without affecting the preproMCH gene expression. This result is in agreement with the fact that MCH serum level diminishes during the antidepressant treatment in MD, and supports the hypothesis that an increase in the MCHergic activity could have pro-depressive consequences. (C) 2016 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V.